|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on July 18, 2002; DOI 10.1182/blood-2002-02-0504.
HEMATOPOIESIS
From the Ontario Cancer Institute and Departments of
Medical Biophysics, and Laboratory Medicine and Pathobiology,
University of Toronto, Toronto, Ontario, Canada.
Various cytokines have been shown to protect cells from
p53-dependent apoptosis. To investigate the mechanism underlying
cytokine-mediated survival, we used a Friend virus-transformed
erythroleukemia cell line that expresses a temperature-sensitive p53
allele. These cells express the spleen focus-forming virus-encoded
envelope glycoprotein gp55 that allows the cells to proliferate in the absence of erythropoietin (EPO). These cells respond to p53 activation at 32°C by undergoing G1 cell cycle arrest and apoptosis.
In the presence of EPO, p53 activation leads only to prolonged but
viable G1 arrest. These findings indicate that EPO
functions as a survival factor and that gp55/EPO receptor signaling is
distinct from EPO/EPO receptor signaling. We demonstrate that
p53-dependent apoptosis results in mitochondrial damage as shown by
loss of mitochondrial membrane potential, increase in intracellular
calcium, and release of mitochondrial cytochrome c into the
cytosol. EPO prevented all of these changes including the subsequent
activation of caspases. We identify an intrinsic
phosphatidylinositol-3'-OH kinase/protein kinase B
(PI3'K/PKB)-dependent survival pathway that is constitutively active
in these cells. This survival pathway limits p53-dependent apoptosis. We propose that EPO promotes survival through a
distinct pathway that is dependent on JAK2 but independent of STAT5 and PI3'K.
(Blood. 2002;100:3990-4000) The p53 tumor suppressor gene plays a fundamental
role in promoting apoptosis in response to abnormal proliferative
signals and stress including DNA damage.1 Loss of
p53-mediated apoptosis results in the survival of oncogene-expressing
cells undergoing inappropriate cell growth and in the survival of cells
carrying mutations and carcinogenic lesions. Failure to eliminate such cells has been shown to accelerate tumorigenesis.2 The
evasion of apoptosis through genetic or epigenetic mechanisms that
target death and survival pathways is considered to be a hallmark of cancer cells.3
The cellular decision to undergo apoptosis is governed by the
integration of survival and death signals. Growth factors can inhibit
apoptosis through increased expression of prosurvival genes and through
posttranslational modification and inactivation of proapoptotic
proteins. One of the most widely studied cytokines capable of promoting
survival in hematopoietic cells is erythropoietin (EPO). The binding of
EPO to its receptor (EPO-R) activates multiple signaling pathways that
ultimately control the survival, proliferation, and development of
immature erythroid cells (for a review, see Wojchowski et
al4). EPO-dependent tyrosine phosphorylation of the
receptor, which lacks intrinsic kinase activity, and many of its
associated signaling molecules is mediated by the cytoplasmic tyrosine
kinase JAK2. EPO signaling has been shown to rescue committed erythroid
progenitors from undergoing apoptosis during normal erythropoiesis.5,6 The function of EPO as a survival
factor has been confirmed using EPO-dependent erythroid cells in which EPO deprivation results in apoptosis.7-9 Various myeloid
and lymphoid cell lines have been engineered to express wild-type or
mutant forms of the EPO-R and in these cells, EPO-R signaling has also
been shown to prevent apoptosis in response to cytokine withdrawal
10,11 or irradiation.12
In Epo Erythropoietin signaling, through the activation of JAK2, plays
an essential role in regulating the expression of Bcl-XL, a
Bcl-2 family member with antiapoptotic function (for a review, see
Ihle16). The precise mechanism including the possible
involvement of STAT5 in regulating Bcl-XL transcription
remains controversial.16-19
Survival-promoting cytokines have been shown to suppress the function
of the proapoptotic protein BAD by inducing phosphorylation at 2 critical sites, Ser112 and Ser136. The protein kinase Akt/protein kinase B (Akt/PKB), acting downstream of the
phosphatidylinositol-3'-OH kinase (PI3'K) signaling pathway, and RSK1
and RSK2 acting downstream of the mitogen-activated protein
kinase (MAPK) pathway, phosphorylate and inactivate
BAD.20-24 Both of these pathways are activated when EPO
binds to its receptor.4
We have studied the role of EPO in preventing p53-dependent apoptosis
in Friend virus-transformed murine erythroleukemia cells. The DP16.1
cell line was established from erythroid cells present in the spleen of
a DBA/2J mouse infected with the polycythemia-inducing strain of the
Friend virus complex consisting of spleen focus-forming virus
(SFFVP) and Friend murine leukemia virus.25
DP16.1 cells express the SFFVP-encoded env-related
glycoprotein gp55, which binds to the EPO-R and mimics the activation
of the receptor with EPO.26 DP16.1 cells proliferate in
culture independently of added EPO likely as the result of constitutive
EPO-R activation. DP16.1 cells are null for p53, permitting the
generation of a DP16.1/p53ts subline carrying a temperature-sensitive
(ts) p53 transgene. The p53ts protein contains valine instead of
alanine at amino acid position 135 and behaves as a mutant polypeptide at 37°C and as a wild-type polypeptide at 32°C.27
DP16.1/p53ts cells grow well at 37°C but can be induced to undergo
p53-dependent apoptosis at 32°C when the p53ts protein assumes its
wild-type conformation. Using this experimental model, we showed
previously that addition of EPO to the culture medium blocked
p53-dependent apoptosis.28,29 Hence, constitutive
signaling through the EPO-R by gp55 appears to be different from
signaling mediated by EPO/EPO-R interaction. DP16.1/p53ts cells provide
a useful model to investigate the role of EPO in promoting survival
because neither proliferation nor maturation is observed when these
cells are cultured at 32°C in the presence of EPO. In the presence of
EPO, these cells remain viable in a reversible growth-arrested
state.29 Another advantage of this model is that one can
be certain that the apoptotic response is a direct consequence of p53
activity. Other studies have also reported on the ability of specific
cytokines to block p53-dependent death.12,30-32
Here we demonstrate that activation of JAK2 but not STAT5 is required
for EPO-mediated inhibition of p53-dependent apoptosis. Neither PI3'K
nor nuclear factor- Cell culture
Cell cycle analysis
Western blotting Cells were lysed directly in protein sample buffer (2% sodium dodecyl sulfate [SDS], 25 mM Tris [tris(hydroxymethyl)aminomethane]-HCl [pH 6.8], 10% glycerol, 0.1 M dithiothreitol [DTT], 1 mM sodium vanadate, 50 mM sodium fluoride) and boiled for 10 minutes. Protein concentration was estimated by the Sigma Protein Assay (Sigma-Aldrich, St Louis, MO). Total protein (80 µg) in the presence of 0.1% bromophenol blue was loaded onto a polyacrylamide gel containing SDS, subjected to electrophoresis, transferred onto polyvinylidene difluoride (PVDF) membranes, and incubated with the appropriate antibodies. The phospho-STAT5 antibody recognizes the tyrosine-phosphorylated form of STAT5 (Tyr694).33 The phospho-STAT1 antibody was from Zymed Laboratories (San Francisco, CA). The phospho-PKB antibody recognizes the serine-phosphorylated form of PKB (Ser473; New England Biolabs, Beverly, MA). The phospho-BAD monoclonal antibody recognizes the serine-phosphorylated form of BAD (Ser112; Cell Signaling Technology, Beverly, MA). Antibodies directed to poly(ADP-ribose) polymerase (clone 2C-10, gift of G. Poirier, CHUL Research Centre, Ste-Foy, QC, Canada), Bcl-XL (BD Biosciences Pharmingen, San Diego, CA), Bax (Santa Cruz Biotechnology, Santa Cruz, CA), retinoblastoma protein (pRB; BD Biosciences Pharmingen), cytochrome c (BD Biosciences Pharmingen), PKB (New England Biolabs), STAT1 and STAT3 (BD Biosciences Pharmingen), BAD (Cell Signaling Technology), and -actin (Sigma-Aldrich) were used in this study.
Equal protein loading of each sample was verified by Coomassie blue
staining of the polyacrylamide gel after transfer or by reprobing of
the membranes with a -actin antibody.
Immunoprecipitation and Western blotting for detection of JAK and STAT phosphorylation Cells (2 × 107) were lysed on ice for 30 minutes in 500 µL lysis buffer (20 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% NP40, 1 mM sodium vanadate, 50 mM sodium fluoride, 100 µg/mL Pefabloc, 1 µg/mL each of pepstatin A, aprotinin, and leupeptin). Cell debris was removed by centrifugation at 12 000 rpm for 15 minutes at 4°C. The supernatants (1-2 mg protein) were incubated with antibodies (5 µg) specific for JAK1 or JAK2 (Upstate Biotechnology, Lake Placid, NY) or STAT3 (Zymed Laboratories) for 60 minutes at 4°C and then with 50 µL protein A-Sepharose beads (Amersham Biosciences, Piscataway, NJ) for a further 60 minutes at 4°C. The beads were collected by centrifugation; samples were boiled for 5 minutes and proteins were separated on a 7.5% polyacrylamide gel containing SDS prior to transfer to a PVDF membrane. Blots were incubated with antibodies and immune complexes were visualized with chemiluminescence reagents (Perkin Elmer Life Sciences, Boston, MA). A phosphotyrosine-specific antibody PY20 (Santa Cruz Biotechnology) was used to detect phosphorylated JAK1 and JAK2 proteins, and 4G10 (Upstate Biotechnology) was used to detect phosphorylated STAT3. The blots were reprobed with JAK1-, JAK2-, or STAT3-specific antibodies to reveal total JAK1, JAK2, or STAT3 protein, respectively.Two-dimensional gel electrophoresis The DP16.1/p53ts cells were lysed in 8 M urea, 4% 3[3-cholaminopropyl diethyl-ammonio]-1-propane sulfonate (CHAPS), 40 mM Tris base, and 100 mM DTT supplemented with protease and phosphatase inhibitors. Protein extracts were passed through a QIAshredder to reduce viscosity and separated by 2-dimensional gel electrophoresis. Immobilized pH gradient (IPG) strips (linear pH 3-10) were used for separation in the first dimension using the IPGphor Isoelectric Focusing System (Amersham Biosciences). Protein separation in the second dimension was achieved by SDS-12% polyacrylamide gel electrophoresis (PAGE).Isolation of cytosolic cytochrome c Cytosolic protein fractions were prepared as previously described.34 Cytochrome c was identified in the cytosolic fractions by Western blotting.Apoptosis analysis Three assays were used for analysis of apoptotic cells. These assays produced comparable results when we used them to test identical samples of DP16.1/p53ts cells.TUNEL assay. Cells were fixed in 4% formaldehyde followed by 70% ethanol. Then, 3 × 105 cells were resuspended in a 50-µL labeling reaction (25 mM Tris-HCl [pH 6.6], 200 mM potassium cacodylate, 2.5 mM CoCl2, 20 µM biotin-16-deoxyuridine triphosphate [dUTP], 10 µM deoxythymidine triphosphate [dTTP], 1.25 mg/mL BSA, and 12.5 U terminal transferase) and incubated at 37°C for 45 minutes. Cells were washed twice in PBS and incubated with FITC-conjugated avidin in 200 µL 4 × standard sodium citrate (SSC) buffer (1 × SSC is 0.15 M NaCl plus 0.015 M sodium citrate) containing 5% skim milk and 0.1% Tween 20 for 30 minutes at room temperature. Apoptotic cells stained by FITC fluorescence were analyzed by flow cytometry. Annexin V staining. Staining of apoptotic cells with phycoerythrin (PE)-conjugated annexin V was performed according to the supplier (BD Biosciences Pharmingen). Apoptotic cells were analyzed by flow cytometry. Cell count based on morphology. Cells were suspended in PBS containing trypan blue dye and counted under a light microscope. Cells stained blue were excluded from analysis. The percentage of apoptotic cells was based on the number of apoptotic cells in a total of 200 cells. Apoptotic cells were identified on the basis of their typical morphology (condensed nuclei and cell shrinkage). Measurement of mitochondrial membrane potential, reactive oxygen species, glutathione, and free calcium An EPICS Elite cell sorter (Beckman Coulter), equipped with 3 lasers emitting at 325 nm, 488 nm, and 633 nm, was used to analyze reactive oxygen species (ROS), glutathione content, intracellular free calcium, and mitochondrial membrane potential. All fluorescent dyes were purchased from Molecular Probes (Eugene, OR) and the staining methods were described in detail elsewhere.35 Briefly, 5 µM carboxy-dichlorofluorescein diacetate (carboxy-DCFDA) was used to detect ROS. Carboxy-DCFDA was excited at 488 nm and fluorescence collected at 525 nm. As a positive control for the generation of ROS, the oxidant tert-butyl hydroperoxide (Sigma-Aldrich) was added to the cells 15 minutes before analysis by flow cytometry. Monobromobimane (40 µM) was used to detect the cellular content of reduced glutathione. Acetoxymethyl ester (3 µM indo-1) was used to detect intracellular calcium. Both monobromobimane and indo-1 were excited at 325 nm; the monobromobimane fluorescence was collected with a 440-nm bandpass filter and the intracellular free calcium was measured as a ratio of calcium-bound (405 nm) and calcium-free (525 nm) emissions of indo-1. DiIC1(5) (40 nM) was used to measure mitochondrial membrane potential. DiIC1(5) was excited at 633 nm and fluorescence collected at 675 nm. PI (5 µg/mL) was added to all samples to identify cells that had lost cytoplasmic membrane integrity.Electrophoretic mobility shift assay Assays for the DNA-binding activity of STAT536 and NF B37 were performed with minor changes. To prepare
nuclear extracts, EPO-treated or untreated cells were lysed in buffer A
(20 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid, pH 7.8], 20% glycerol, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM EDTA [ethylenediaminetetraacetic acid], 1 mM DTT, 0.1%
NP40, and protease inhibitor cocktail [Roche Applied Science,
Indianapolis, IN]) and kept on ice for 5 minutes. Extracts were
centrifuged and the nuclear pellet was lysed in 3 volumes of buffer A
modified to contain 400 mM NaCl and 1% NP40. A 20-µL binding
reaction mixture contained 4 µL nuclear lysate (10 µg protein), 1 µg poly(dI-dC), 5 × 104 cpm 32P-labeled
double-stranded probe, 20 mM HEPES (pH 7.8), 100 mM NaCl, 1 mM DTT, 1 mM MgCl2, 0.5 mM EDTA, and 8% glycerol. An
end-labeled double-stranded oligonucleotide derived from the
-casein promoter (5'-AGATTTCTAGGAATTCAAATC-3')
was used as the probe for STAT5 and an unlabeled oligonucleotide from
the DUB-1 promoter (5'-TAACAGGAAATAATGACTAAG-3') was
used as a negative control in the competition reaction.36 An end-labeled oligonucleotide probe derived from the HIV-1 long terminal repeat (LTR; 5'-CGGAAAGTCCCCAGCGGAAAGTCCCTGAT-3') was used to measure NFB DNA-binding activity. Tumor necrosis factor  (TNF-, gift from C. Richardson, Ontario Cancer Institute, Toronto, ON, Canada) was used to stimulate the DNA-binding activity of NFB.
Transient expression of DN JAK2 and STAT5 Two DN JAK2 expression constructs were used in this study. pEFBOS-JAK2 829 contains a carboxy-terminal truncation of JAK2 and
pEFBOS-JAK2-DK contains point mutations in the kinase domain resulting
in the loss of kinase activity.11 The STAT5 DN construct in pcDNA3 encodes a truncated form of STAT5 with a stop codon at amino
acid position 650, producing a protein of approximately 72 kDa.36 Transient transfection of the DN JAK2 constructs
into DP16.1/p53ts cells was performed with the Superfect reagent
(Qiagen, Valencia, CA) according to protocols supplied by the
manufacturer. After transfection, cells were cultured with or without
EPO (1 U/mL) at 32°C overnight and collected for apoptosis analysis
by TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling) staining. The DN STAT5 construct was cotransfected into DP16.1/p53ts cells with a CD20 expression plasmid using the FuGene
reagent (Roche Applied Science). Eighteen to 20 hours after transfection, cells were cultured with or without EPO (1 U/mL) at
32°C overnight. A gate was set to select the CD20+ cells
and annexin V staining was used to measure apoptosis.
Measurement of STAT5 phosphorylation by flow cytometry The DP16.1/p53ts cells (2 × 106), either left untreated or treated with EPO (1 U/mL) for 15 minutes, were fixed in cold 70% methanol on ice for 30 minutes, washed 3 times with cold PBS containing 0.5% BSA (PBS-BSA), resuspended in PBS containing goat serum, and incubated at room temperature for 45 minutes. Cells were spun, resuspended in 200 µL PBS-3% BSA containing phospho-Stat5 (Tyr694) antibodies (New England Biolabs) used at a 1:200 dilution, and incubated at 4°C for 16 hours. Cells were washed twice with cold PBS-BSA containing 0.05% Triton-X 100, once with PBS-BSA, resuspended in 200 µL PBS-3% BSA containing secondary antibody (FITC-conjugated rabbit anti-mouse immunoglobulin G) used at a 1:1000 dilution, and incubated at room temperature for 1 hour in the dark. Cells were washed 3 times in PBS-BSA and analyzed by flow cytometry (FACScan, BD Biosciences).
EPO blocks p53-dependent apoptosis The DP16.1/p53ts cells were transferred to a 32°C incubator and cultured in the presence or absence of EPO. As measured by the TUNEL assay, p53 activation resulted in 30% cell death by 24 hours (Figure 1A). The surviving cells were arrested in the G1 phase of the cell cycle (Figure 1B). Nearly all cells were dead by 72 hours after p53 activation (data not shown). In the presence of EPO, however, the extent of cell death at 24 hours was reduced to 3.5% (Figure 1A) and the cells underwent a prolonged and viable blockade in G1 (Figure 1B and data not shown). The p53-mediated G1 arrest was associated with an increase in the hypophosphorylated isoforms of pRB in both EPO-treated and untreated cells (Figure 1C) consistent with p53-dependent induction of the cyclin-dependent kinase inhibitor p21WAF1 (Figure 1D). In addition, EPO did not prevent p53-dependent induction of Bax 38 and Pidd,39 2 genes implicated in p53-mediated apoptosis (data not shown). These data indicate that EPO does not block the sequence-specific transactivation function of p53 and that EPO-mediated signals interfere with p53-dependent apoptosis but not with p53-dependent G1 arrest.
EPO inhibits the release of cytochrome c, the decrease in mitochondrial membrane potential, and the activation of caspases associated with p53-dependent apoptosis It has been shown that p53-dependent apoptosis proceeds through a pathway that involves Apaf-1 and caspase 9 activation downstream of mitochondrial cytochrome c release.40,41 We wished to determine if p53-dependent apoptosis in DP16.1/p53ts cells involves mitochondrial cytochrome c release and whether EPO promotes survival by inhibiting the release of cytochrome c. DP16.1/p53ts cells were cultured at 32°C for increasing periods of time and cytosolic fractions were prepared for Western blotting. Cytochrome c levels in the cytosol were significantly increased by 8 hours after the temperature shift (Figure 2A). In other experiments, cytochrome c release was evident as early as 4 hours after the temperature shift (data not shown). The kinetics of cytochrome c release were consistent with the kinetics of p53-mediated cell death.29 The release of cytochrome c from the mitochondria was reduced markedly when the cells were cultured in the presence of EPO (Figure 2A).
Release of cytochrome c into the cytosol is usually preceded or accompanied by a drop in the mitochondrial membrane potential. We observed a drop in the mitochondrial membrane potential when DP16.1/p53ts cells were cultured at 32°C for 16 hours (Figure 2B). Intracellular free calcium also increased in a subpopulation that had suffered loss of mitochondrial membrane potential (Figure 2B). Release of ionized calcium is an indication of disturbance in mitochondrial function. In cells treated with EPO, both the decrease in mitochondrial membrane potential and the increase in free calcium were inhibited (Figure 2B). In addition, we detected cleavage of the caspase 3 substrate, poly(ADP-ribose) polymerase (PARP) during p53-dependent apoptosis and found that PARP cleavage was effectively reduced in response to EPO (Figure 2C). Taken together, these results demonstrate that p53-mediated cell death involves signaling through the mitochondria and that EPO provides protection from p53-dependent apoptosis by acting at an early stage to preserve mitochondrial integrity and prevent caspase activation. We then looked for an association between p53-dependent apoptosis and the generation of ROS in DP16.1/p53ts cells because p53-dependent apoptosis has been reported to be dependent on ROS production.42-44 DP16.1/p53ts cells were cultured at 32°C and collected at 0, 8 and 16 hours, and the level of ROS and glutathione determined using a flow cytometric assay. We did not detect any increase in ROS or loss of glutathione content after p53 was activated (Figure 2D). DP16.1/p53ts cells treated with the oxidant tert-butyl hydroperoxide served as a positive control and showed the expected production of ROS and loss of glutathione content. In additional experiments, we were unable to detect ROS at earlier time points (2 hours, 4 hours) or later time points (20 hours, 24 hours) after p53 activation (data not shown). These findings indicate that in DP16.1/p53ts cells, p53 activation leads to apoptosis through a pathway that does not involve the generation of ROS. EPO inhibition of p53-dependent apoptosis is associated with JAK2 and STAT5 activation but not JAK1 activation Binding of the SFFVp env-related gp55 glycoprotein to the EPO-R is associated with constitutive JAK1 activation in SFFVP-infected cells,45 whereas ligand-induced EPO-R homodimerization leads to activation of the cytoplasmic tyrosine kinase JAK2. We wished to determine if the JAK/STAT pathway could be activated in SFFVP-transformed DP16.1/p53ts cells on EPO-R stimulation and whether activation of this pathway was associated with the suppression of p53-dependent apoptosis. DP16.1/p53ts cells were cultured at 37°C or at 32°C for 12 hours and then treated with EPO for 15 minutes just prior to lysis. JAK1 and JAK2 were immunoprecipitated from the cell lysates with anti-JAK1 and anti-JAK2 antibodies, respectively. The immunoprecipitates were analyzed by Western blotting with antiphosphotyrosine antibody PY20 or with anti-JAK1 or anti-JAK2 antibody. As shown in Figure 3A, only JAK1 was constitutively tyrosine phosphorylated and EPO treatment did not increase JAK1 phosphorylation. There was no change in JAK1 phosphorylation whether or not p53 was activated at 32°C. In contrast, there was very little tyrosine phosphorylation of JAK2 in DP16.1/p53ts cells cultured at 37°C or 32°C. Within 15 minutes of EPO addition to the culture medium, tyrosine phosphorylation of JAK2 was markedly increased.
We examined tyrosine phosphorylation of the JAK2 substrates STAT1,
STAT3, and STAT5 in DP16.1/p53ts cells in response to EPO stimulation.
STAT3 and STAT5 protein are expressed in these cells but we could not
detect STAT1 protein by Western blotting. Constitutive activation of
these STATs was not observed. Within 15 minutes of EPO stimulation,
tyrosine phosphorylation of STAT5, but not of STAT1 or STAT3, was
readily detected (Figure 3A-B). In addition, EPO stimulation rapidly
induced STAT5 DNA-binding activity as detected by its interaction with
a DNA sequence derived from the EPO-mediated inhibition of p53-dependent apoptosis requires JAK2 To assess the importance of JAK2 in EPO suppression of p53-mediated apoptosis, we used DN JAK2 mutants to disrupt endogenous JAK2 function. JAK2829 contains a carboxy-terminal truncation and
JAK2-DK contains point mutations in the kinase domain resulting in the
loss of kinase activity.11 Both mutants are effective in
preventing EPO-dependent cell proliferation and
survival.11 DP16.1/p53ts cells were transfected with the
DN JAK2 mutants and incubated at 32°C to activate p53 in the presence
or absence of EPO. Cells were collected 12 hours after p53 activation
and the proportion of cells undergoing apoptosis was measured by the
TUNEL assay as described in "Materials and methods." The results,
presented in Figure 4A, show that
transient expression of both DN JAK2 mutants, but not transfection with
the empty vector, effectively blocked the ability of EPO to promote
survival of cells with activated p53. These data indicate that JAK2
function is required for EPO inhibition of p53-dependent apoptosis.
EPO-mediated inhibition of p53-dependent apoptosis is not dependent on STAT5 To assess the importance of STAT5 in EPO suppression of p53-mediated apoptosis, a DN form of STAT536 truncated at amino acid 650 was transiently expressed in DP16.1/p53ts cells. This mutant is defective in tyrosine phosphorylation, heterodimerization, DNA binding, and transcriptional activation. It acts as a DN form likely by blocking wild-type STAT binding to the intracytoplasmic domain of the EPO-R.36,46 In a preliminary series of experiments, we found that expression of DN STAT5 did not diminish the ability of EPO to promote survival of DP16.1/p53ts cells cultured at 32°C to activate p53. To confirm this finding, a vector encoding DN STAT5 was cotransfected with an expression vector encoding the B-cell surface marker CD20. Transfected cells were identified by CD20 staining and the proportion of CD20+ cells undergoing p53-dependent apoptosis at 32°C in the presence or absence of EPO was determined by annexin V staining and flow cytometry. EPO suppressed apoptosis to the same extent in CD20+ cells transfected with DN STAT5 as in CD20+ cells transfected with empty vector (Figure 4B).To ensure that the DN STAT5 construct was effective at inhibiting the activation of endogenous STAT5 in response to EPO, we measured the level of phosphorylated STAT5 in cells that were transfected with CD20 and DN STAT5. Cells were fixed and stained with a phospho-specific antibody against STAT5 (Tyr694), and the level of staining was measured using a flow cytometry-based assay. The left panel in Figure 4C demonstrates that EPO stimulation of untransfected DP16.1 cells resulted in STAT5 phosphorylation that could be detected using this assay. Furthermore, STAT5 was phosphorylated in response to EPO in CD20+ cells transfected with CD20 and empty vector (Figure 4C, middle panel), but not in CD20+ cells transfected with CD20 and the DN STAT 5 construct (Figure 4C, right panel). Together, these data indicate that EPO-mediated survival of DP16.1/p53ts cells at 32°C requires JAK2 but is independent of STAT5. The PI3'K/PKB-signaling pathway limits p53-dependent apoptosis but is not required for EPO-mediated protection PI3'K is one of several molecules that is recruited to the activated EPO-R either directly47 or indirectly through Gab148 or IRS-2.49 To determine if the PI3'K pathway is constitutively active in gp55-expressing SFFVP-transformed erythroleukemia cells, or whether this pathway can be induced following EPO stimulation, we examined the phosphorylation state of Akt/PKB, a key signaling effector of the PI3'K pathway essential for the survival of at least some cell types.50,51 DP16.1/p53ts cells were treated with EPO in the presence or absence of wortmannin (100 nM), a PI3'K inhibitor, and cell extracts were prepared for analysis by Western blotting using a phospho-PKB antibody that specifically recognizes PKB with phosphoserine at position 473. Figure 5A shows that PKB was constitutively phosphorylated on Ser473 and that addition of EPO to the culture medium did not cause a further increase in PKB phosphorylation. Wortmannin treatment reduced PKB phosphorylation whether or not EPO was present. This indicates that PI3'K activity is an upstream activator of PKB in DP16.1 cells.
To assess the importance of constitutive PI3'K/PKB signaling for the survival of SFFVP-transformed cells under normal growth conditions and under conditions in which p53 is activated, we inhibited this pathway with the PI3'K inhibitors wortmannin (100 nM) and LY294002 (5 µM). DP16.1 and DP16.1/p53ts cells were cultured at 37°C or 32°C for 12 hours in the presence of absence of the inhibitors. Apoptotic cells were identified on the basis of their typical morphology and enumerated under the microscope. This method for scoring apoptosis was found to be comparable with the TUNEL assay. Wortmannin and LY294002 had little or no effect on the viability of the parental DP16.1 cells, cultured at either temperature, or on DP16.1/p53ts cells cultured at 37°C (Figure 5B). In the presence of activated p53 at 32°C, however, the extent of p53-dependent apoptosis was markedly increased on PI3'K inhibition. We confirmed this observation using a subclone of DP16.1/p53ts cells (R) that was selected on the basis of its inability to undergo p53-dependent apoptosis at 32°C. At 37°C, PI3'K inhibition had no effect on the apoptotic index of these cells. At 32°C, however, PI3'K inhibition resulted in significant cell death (Figure 5B). These results indicate that an intrinsic survival pathway involving PI3'K and PKB is constitutively activated in DP16.1 cells and that this pathway effectively limits p53-dependent apoptosis. The PTEN tumor suppressor gene (phosphatase and tensin homolog) was recently shown to be regulated at the transcriptional level by p53.52 PTEN encodes a lipid phosphatase that removes the 3'-phosphate on phosphatidylinositol-3,4,5-triphosphate (PIP3). PI3'K-dependent synthesis of PIP3 is required for the phosphorylation and activation of PKB by PDK1. By decreasing the level of PIP3, PTEN serves as a negative regulator of the PI3'K/PKB pathway. In DP16.1/p53ts cells, activation-specific phosphorylation of PKB was reduced at time points coincident with maximal p53-dependent PTEN induction.52 This observation raised the possibility that EPO might promote survival by maintaining PKB in its phosphorylated and activated state. The blot shown in Figure 5C demonstrates that PKB phosphorylation was reduced at 7 hours following p53 activation at 32°C and that this reduction was unaffected by EPO. Hence, EPO does not appear to act through PKB. To confirm that the protection afforded by EPO is not mediated through the PI3'K/PKB pathway, we treated DP16.1/p53ts cells with EPO at 32°C in the presence of increasing concentrations of the LY294002 inhibitor (Figure 5D). As expected, the extent of p53-dependent apoptosis increased on addition of LY294002. Nevertheless, EPO was still able to reduce apoptosis and promote cell survival. EPO led to a 65% reduction of p53-mediated cell death at 0 µM and 2 µM LY294002, and a 55% reduction of apoptosis in the presence of 10 µM LY294002 (Figure 5D). Hence, EPO retains the ability to protect DP16.1/p53ts cells from p53-dependent cell death in the presence of LY294002. The proapoptotic protein BAD is phosphorylated on
multiple serine residues. The PKB-mediated phosphorylation on
Ser136 results in its inactivation. We were interested, therefore, in
determining whether the intrinsic PI3'K/PKB-dependent survival pathway
acts through BAD. We performed an analysis of BAD protein isoforms by
2-dimensional gel electrophoresis and Western blotting. At least 7 BAD
protein isoforms were detected in proliferating DP16.1/p53ts cells
(Figure 6). Three of these isoforms were
lost when cells were treated with the PI3'K inhibitor LY294002 or with
EPO stimulation leads to increased expression of Bcl-XL Overexpression of Bcl-2 and its family member Bcl-XL have been shown to overcome p53-induced apoptosis.53-55 We were unable to detect Bcl-2 expression in DP16.1/p53ts cells. To determine if endogenous Bcl-XL expression was increased in DP16.1/p53ts cells in response to EPO stimulation, cell extracts were prepared at 8, 16, and 24 hours after p53 was activated at 32°C and subjected to Western blotting. We found that Bcl-XL protein expression was not markedly influenced by p53 activation at 32°C. A gradual accumulation of Bcl-XL protein was observed after addition of EPO reaching approximately 5-fold after 24 hours (Figure 7A). This increase in Bcl-XL protein was associated with only a 1.5-fold increase in Bcl-XL mRNA (data not shown). Hence, in DP16.1/p53ts cells, Bcl-XL expression appears to be regulated primarily through a posttranscriptional mechanism in response to EPO. Bax protein and RNA expression increased approximately 2-fold in response to p53 activation and these levels were not influenced by EPO (Figure 7A and data not shown).
To investigate if EPO might control the expression or activation of Bcl-XL through posttranslational changes, we performed an analysis of Bcl-XL protein isoforms by 2-dimensional gel electrophoresis and Western blotting (Figure 7B). Exposure of the cells to EPO resulted in loss of a more slowly migrating form of Bcl-XL (in the second SDS-PAGE dimension) and the appearance of 3 novel, phosphatase-sensitive isoforms (in the first isoelectric-focusing [IEF] dimension). Together, these findings are consistent with the view that Bcl-XL expression in DP16.1 cells is posttranscriptionally regulated in response to EPO by both phosphorylation-dependent and -independent mechanisms. Moreover, they raise the possibility that Bcl-XL may be an important mediator of EPO-dependent cell rescue. The biochemical basis and functional consequences of these Bcl-XL modifications are being investigated. NF B is an important component of
cell survival signaling pathways in many cell types and can be activated by various cytokines. In neurons, NFB activation appears to be involved in EPO-mediated signaling and in EPO-mediated
neuroprotection.56 To evaluate the potential role of
NFB in mediating protection by EPO, we performed an electrophoretic
mobility shift assay (EMSA) to measure the DNA-binding activity of
NFB in DP16.1/p53ts cells grown with or without EPO. Nuclear
extracts prepared from cells treated with TNF- for 15 and 30 minutes
served as positive controls (Figure 8).
No DNA-binding activity of NFB was detected before or after EPO
stimulation of the cells. These results indicate that NFB is not
constitutively activated in DP16.1/p53ts cells; moreover, NFB is not
activated after EPO stimulation. Thus, it is unlikely that NFB is
involved in the inhibition of p53-dependent apoptosis.
The evasion of apoptosis, through the activation of survival pathways or through the inactivation of proapoptotic pathways, plays an important role in the development of cancer, and is now widely regarded as a hallmark of malignancy. A number of cytokines have been shown to regulate cell growth by promoting survival and in this study we have investigated the mechanism through which EPO prevents p53-dependent apoptosis. The activation of p53 in DP16.1/p53ts cells at 32°C results in cell cycle blockade in G1 and in apoptosis. EPO prevented p53-dependent apoptosis but had no effect on p53-dependent G1 arrest. Importantly, EPO did not interfere with the transactivation function of p53. This indicates that EPO is not targeting p53 directly but rather that it is activating a survival pathway that counteracts apoptosis initiated by p53. The p53-dependent apoptosis was accompanied by disruption of mitochondrial membrane integrity reflected by a decrease in mitochondrial membrane potential, an increase in intracellular free calcium, and the release of mitochondrial cytochrome c into the cytosol. EPO prevented all of these changes including the subsequent activation of caspases. Hence, EPO acts at an early stage to preserve mitochondrial integrity and to protect cells from p53-dependent apoptosis. This experimental model is intriguing because the EPO-independent SFFVP-transformed cells used in this study retain the ability to respond to EPO. The activation of EPO-R molecules by EPO leading to cell survival is clearly different from the mitogenic activation of these same receptors by the SFFVP-encoded gp55. We have shown that JAK2 is phosphorylated in response to EPO and
that JAK2 activation is necessary for EPO-mediated rescue of
p53-induced apoptosis. This is consistent with the fundamental role of
JAK2 in EPO signaling. To begin to identify the components of the
JAK2-dependent signaling pathway important for survival, we examined
STAT family members. STAT5, but not STAT1 or STAT3, was phosphorylated
in response to EPO treatment. STAT5 activation was confirmed by its
sequence-specific DNA-binding activity in the nuclear extract of
DP16.1/p53ts cells treated with EPO. Disruption of endogenous STAT5
function by transient expression of DN STAT5 protein, however, did not
interfere with the ability of EPO to promote survival. Hence, STAT5
appears to be dispensable for EPO-mediated survival. Using an entirely
different experimental model based on cell lines that express various
truncated forms of the EPO-R, Quelle et al12 reported that
the ability of EPO to block apoptosis induced by We observed an increase in Bcl-XL protein expression and posttranslational modification of Bcl-XL protein in response to EPO. These findings raise the possibility that EPO-dependent signaling pathways may mediate survival through activation of Bcl-XL. The increase in protein expression was not accompanied by a similar increase in Bcl-XL mRNA expression. Although there is general agreement that EPO regulates Bcl-XL expression in erythroid cells, there is uncertainty about the underlying mechanism. Our results clearly indicate that Bcl-XL expression is regulated posttranscriptionally in DP16.1/p53ts cells; however, they do not exclude the possibility of transcriptional regulation. The importance of elevated endogenous Bcl-XL expression in rescuing DP16.1/p53ts cells from p53-dependent apoptosis remains to be established. In contrast to the induced activation of JAK2 and STAT5 by EPO, we found that JAK1 and PI3'K were constitutively activated in DP16.1/p53ts cells. JAK1 deficiency in mice leads to severely reduced numbers of thymocytes, pre-B cells, and mature T and B lymphocytes but does not lead to alterations in the development of other hematopoietic lineages; erythropoiesis is normal in JAK1-deficient mice.57 Despite the fact that JAK1 is not required for normal erythroid development and maturation, constitutive activation of JAK1 has been reported in certain transformed cells and can result in cytokine-independent mitogenic signals.58,59 Constitutive activation of JAK1 in Friend virus-transformed erythroleukemia cells was reported previously.45 It is not clear how JAK1 becomes activated in these transformed erythroid cells. One possibility is that the SFFVP-encoded gp55 protein binds to the EPO-R and induces a conformational change in the receptor that is different from the dimerization induced by EPO/EPO-R interaction. In this regard, it is pertinent to note that the Friend virus susceptibility 2 (Fv2) locus encodes a truncated form of the Stk receptor tyrosine kinase (Sf-stk) and it has been suggested that Sf-stk is required for gp55-mediated activation of the EPO-R.60,61 gp55 can bind to Sf-stk resulting in constitutive tyrosine phosphorylation and activation of Sf-stk.62 Hence, the recruitment of accessory signaling molecules by the activated EPO-R may be different in the presence of bound Sf-stk and gp55. A second possibility to explain the constitutive activation of JAK1 is that DP16.1 cells may have undergone secondary genetic changes after viral infection either in vivo during the natural course of virus-induced erythroleukemia or in culture during establishment of the cell line. In erythroid cells, PI3'K is activated in response to EPO
stimulation. Here we report that the PI3'K/PKB pathway is
constitutively activated in SFFVP-transformed DP16.1/p53ts
cells. Constitutive activation of PI3'K has been reported in other
EPO-independent erythroid cell lines.63,64 Our results
demonstrate that PI3'K and PKB represent components of an intrinsic
survival pathway that effectively limits p53-dependent apoptosis in
DP16.1/p53ts cells. Inhibition of the PI3'K pathway with LY294002 or
wortmannin enhanced p53-dependent cell death. These inhibitors had no
detectable effect, at least in the short term, when added to cultures
of p53 It is possible that p53 activation initiates an apoptotic program that simply overwhelms the intrinsic survival pathway and tips the balance toward cell death. Alternatively, p53-dependent apoptosis may require active suppression of the intrinsic survival pathway. The recent demonstration that p53 can activate transcription of PTEN supports the latter possibility.52 We demonstrate that pharmacologic suppression of the PI3'K/PKB pathway is not sufficient to initiate cell death in the absence of p53 activation in DP16.1/p53ts cells. Moreover, we have shown previously that the induction of the p53-responsive gene, Pidd, is required for apoptosis in these cells.39 Together, these results highlight the complexity of p53-mediated, transcriptionally dependent apoptosis and suggest that it involves not only the activation of proapoptotic gene(s) but also the attenuation of intrinsic PI3'K-dependent survival signals. The ability of EPO to inhibit p53-dependent apoptosis was not abrogated by pharmacologic inhibition of PI3'K, suggesting that activation of this pathway is not the primary mechanism by which EPO rescues cells from p53-dependent death. The simplest model to account for these observations is the existence of 2 distinct survival pathways: an intrinsic constitutively active survival pathway dependent on PI3'K/PKB and an extrinsic EPO-inducible pathway dependent on JAK2. The demonstration that STAT5 and PI3'K are dispensable for EPO-mediated survival of DP16.1/p53ts cell following p53 activation indicates that other components in the JAK2 signaling pathway are important for survival.
The authors wish to thank Weili Ma for excellent technical assistance.
Submitted February 14, 2002; accepted July 4, 2002.
Prepublished online as Blood First Edition Paper, July 18, 2002; DOI 10.1182/blood-2002-02-0504.
Supported by the National Cancer Institute of Canada with funds from the Canadian Cancer Society (S.B.) and by the Canadian Institutes of Health Research (S.B. and D.L.B.). D.L.B. is a research scientist of the National Cancer Institute of Canada and L.B. is supported by a postgraduate scholarship from the Natural Sciences and Engineering Research Council of Canada.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Samuel Benchimol, Ontario Cancer Institute, 610 University Ave, Toronto, ON M5G 2M9, Canada; e-mail: benchimo{at}uhnres.utoronto.ca.
1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331[CrossRef][Medline] [Order article via Infotrieve]. 2. Symonds HL, Krall L, Remington M, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 1994;78:703-711[CrossRef][Medline] [Order article via Infotrieve]. 3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70[CrossRef][Medline] [Order article via Infotrieve]. 4. Wojchowski DM, Gregory RC, Miller CP, Pandit A, Pircher TJ. Signal transduction in the erythropoietin receptor system. Exp Cell Res. 1999;253:143-156[CrossRef][Medline] [Order article via Infotrieve].
5.
Kelley LL, Koury MJ, Bondurant MC, Koury ST, Sawyer ST, Wickrema A.
Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production.
Blood.
1993;82:2340-2352
6.
Koury MJ, Bondurant MC.
Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells.
Science.
1990;248:378-381
7.
Jacobs-Helber SM, Wickrema A, Birrer MJ, Sawyer ST.
AP1 regulation of proliferation and initiation of apoptosis in erythropoietin-dependent erythroid cells.
Mol Cell Biol.
1998;18:3699-3707
8.
Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL.
Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2.
Blood.
1996;88:1576-1582
9.
Tilbrook PA, Bittorf T, Busfield SJ, Chappell D, Klinken SP.
Disrupted signaling in a mutant J2E cell line that shows enhanced viability, but does not proliferate or differentiate, with erythropoietin.
J Biol Chem.
1996;271:3453-3459
10.
Gaffen SL, Lai SY, Longmore GD, Liu KD, Goldsmith MA.
Genetic evidence for an additional factor required for erythropoietin-induced signal transduction.
Blood.
1999;94:74-86
11.
Zhuang H, Niu Z, He TC, Patel SV, Wojchowski DM.
Erythropoietin-dependent inhibition of apoptosis is supported by carboxyl-truncated receptor forms and blocked by dominant-negative forms of JAK2.
J Biol Chem.
1995;270:14500-14504
12.
Quelle FW, Wang J, Feng J, et al.
Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways.
Genes Dev.
1998;12:1099-1107 13. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995;83:59-67[CrossRef][Medline] [Order article via Infotrieve]. 14. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93:397-409[CrossRef][Medline] [Order article via Infotrieve]. 15. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93:385-395[CrossRef][Medline] [Order article via Infotrieve]. 16. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol. 2001;13:211-217[CrossRef][Medline] [Order article via Infotrieve].
17.
Silva M, Benito A, Sanz C, et al.
Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin-dependent progenitor cell lines.
J Biol Chem.
1999;274:22165-22169
18.
Socolovsky M, Fallon AEJ, Wang S, Brugnara C, Lodish HF.
Fetal anemia and apoptosis of red cell progenitors in Stat5a 19. Teglund S, McKay C, Schuetz E, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998;93:841-850[CrossRef][Medline] [Order article via Infotrieve].
20.
Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME.
Cell survival promoted by the Ras-MAPK signalling pathway by transcription-dependent and -independent mechanisms.
Science.
1999;286:1358-1362
21.
del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G.
Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.
Science.
1997;278:687-689 22. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241[CrossRef][Medline] [Order article via Infotrieve]. 23. Shimamura A, Ballif BA, Richards SA, Blenis J. Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr Biol. 1999;10:127-135. 24. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell. 1996;87:619-628[CrossRef][Medline] [Order article via Infotrieve]. 25. Mowat M, Cheng A, Kimura N, Bernstein A, Benchimol S. Rearrangements of the cellular p53 gene in erythroleukemic cells transformed by Friend virus. Nature. 1985;314:633-636[CrossRef][Medline] [Order article via Infotrieve]. 26. Li JP, D'Andrea AD, Lodish HF, Baltimore D. Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature. 1990;343:762-764[CrossRef][Medline] [Order article via Infotrieve]. 27. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 1990;62:671-680[CrossRef][Medline] [Order article via Infotrieve].
28.
Johnson P, Chung S, Benchimol S.
Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin.
Mol Cell Biol.
1993;13:1456-1463 29. Lin Y, Benchimol S. Cytokines inhibit p53-mediated apoptosis but not p53-mediated G1 arrest. Mol Cell Biol. 1995;15:6045-6054[Abstract]. 30. Abrahamson JL, Lee JM, Bernstein A. Regulation of p53-mediated apoptosis and cell cycle arrest by Steel factor. Mol Cell Biol. 1995;15:6953-6960[Abstract].
31.
Canman CE, Gilmer TM, Coutts SB, Kastan MB.
Growth factor modulation of p53-mediated growth arrest versus apoptosis.
Genes Dev.
1995;9:600-611 32. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991;352:345-347[CrossRef][Medline] [Order article via Infotrieve].
33.
Gollob JA, Murphy EA, Mahajan S, Schnipper CP, Ritz J, Frank DA.
Altered interleukin-12 responsiveness in Th1 and Th2 cells is associated with the differential activation of STAT5 and STAT1.
Blood.
1998;91:1341-1354 34. Bossy-Wetzel E, Green DR. Assays for cytochrome c release from mitochondria during apoptosis. Methods Enzymol. 2000;322:235-242[Medline] [Order article via Infotrieve].
35.
Backway KL, McCulloch EA, Chow S, Hedley DW.
Relationships between the mitochondrial permeability transition and oxidative stress during ara-C toxicity.
Cancer Res.
1997;57:2446-2451 36. Jaster R, Zhu Y, Pless M, Bhattacharya S, Mathey-Prevot B, D'Andrea AD. JAK2 is required for induction of the murine DUB-1 gene. Mol Cell Biol. 1997;17:3364-3372[Abstract]. 37. Yeh WC, Shahinian A, Speiser D, et al. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity. 1997;7:715-725[CrossRef][Medline] [Order article via Infotrieve]. 38. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293-299[CrossRef][Medline] [Order article via Infotrieve]. 39. Lin Y, Ma W, Benchimol S. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat Genet. 2000;26:122-125[CrossRef][Medline] [Order article via Infotrieve].
40.
Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR.
p53 induces apoptosis by caspase activation through mitochondrial c release.
J Biol Chem.
2000;275:7337-7342
41.
Soengas MS, Alarcon RM, Yoshida H, et al.
Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition.
Science.
1999;284:156-159
42.
Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, Finkel T.
Reactive oxygen species are downstream mediators of p53-dependent apoptosis.
Proc Natl Acad Sci U S A.
1996;93:11848-11852 43. Li PF, Dietz R, von Harsdorf R. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J. 1999;18:6027-6036[CrossRef][Medline] [Order article via Infotrieve]. 44. Polyak K, Xia Y, Zweler JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997;389:300-305[CrossRef][Medline] [Order article via Infotrieve].
45.
Yamamura Y, Senda H, Kageyama Y, Matsuzaki T, Noda M, Ikawa Y.
Erythropoietin and Friend virus gp55 activate different JAK/STAT pathways through the erythropoietin receptor in erythroid cells.
Mol Cell Biol.
1998;18:1172-1180
46.
Ilaria RL Jr, Hawley RG, Van Etten RA.
Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation.
Blood.
1999;93:4154-4166
47.
Damen JE, Cutler RL, Jiao H, Yi T, Krystal G.
Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity.
J Biol Chem.
1995;270:23402-23408
48.
Lecoq-Lafon C, Verdier F, Fichelson S, et al.
Erythropoietin induces the tyrosine phosphorylation of GAB1 and its association with SHC, SHP2, SHIP, and phosphatidylinositol 3-kinase.
Blood.
1999;93:2578-2585
49.
Verdier F, Chretien S, Billat C, Gisselbrecht S, Lacombe C, Mayeux P.
Erythropoietin induces the tyrosine phosphorylation of insulin receptor substrate-2. An alternate pathway for erythropoietin-induced phosphatidylinositol 3-kinase activation.
J Biol Chem.
1997;272:26173-26178 50. Scheid MP, Lauener RW, Duronio V. Role of phosphatidylinositol 3'-OH kinase activity in the inhibition of apoptosis in hemopoietic cells: phosphatidylinositol 3-OH-kinase inhibitors reveal a difference in signaling between interleukin-3 and granulocyte-macrophage colony stimulating factor. Biochem J. 1995;312:159-162[Medline] [Order article via Infotrieve].
51.
Yao R, Cooper GM.
Requirement for phosphatidylinositol-3' kinase in the prevention of apoptosis by nerve growth factor.
Science.
1995;267:2003-2006 52. Stambolic V, MacPherson D, Sas D, et al. Regulation of PTEN transcription by p53. Mol Cell. 2001;8:317-325[CrossRef][Medline] [Order article via Infotrieve].
53.
Chiou SK, Rao L, White E.
Bcl-2 blocks p53-dependent apoptosis.
Mol Cell Biol.
1994;14:2556-2563 54. Schott AF, Apel IJ, Nunez G, Clarke MF. Bcl-xL protects cancer cells from p53-mediated apoptosis. Oncogene. 1995;11:1389-1394[Medline] [Order article via Infotrieve]. 55. Wang Y, Szekely L, Okan I, Klein G, Wiman KG. Wild-type p53 triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene. 1993;8:3427-3431[Medline] [Order article via Infotrieve].
56.
Digicaylioglu M, Lipton SA.
Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF- 57. Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998;93:373-383[CrossRef][Medline] [Order article via Infotrieve].
58.
Campbell GS, Yu CL, Jove R, Carter-Su C.
Constitutive activation of JAK1 in Src-transformed cells.
J Biol Chem.
1997;272:2591-2594
59.
Lacronique V, Bouruex A, Monni R, et al.
Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells.
Blood.
2000;95:2076-2083
60.
Ney P, D'Andrea AD.
Friend erythroleukemia revisited.
Blood.
2000;96:3675-3680 61. Persons DA, Paulson RE, Loyd MR, et al. Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat Genet. 1999;23:159-165[CrossRef][Medline] [Order article via Infotrieve].
62.
Nishigaki K, Thompson D, Hanson C, Yugawa T, Ruscetti S.
The envelope glycoprotein of friend spleen focus-forming virus covalently interacts with and constitutively activates a truncated form of the receptor tyrosine kinase stk.
J Virol.
2001;75:7893-7903
63.
Bao H, Jacobs-Helber SM, Lawson AE, Penta K, Wickrema K, Sawyer ST.
Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells).
Blood.
1999;93:3757-3773
64.
Nishigaki K, Hanson C, Ohashi T, Thompson D, Muszynski K, Ruscetti S.
Erythroid cells rendered erythropoietin independent by infection with Friend spleen focus-forming virus show constitutive activation of phosphatidylinositol 3-kinase and Akt kinase: Involvement of insulin receptor substrate-related adapter proteins.
J Virol.
2000;74:3037-3045
65.
Sabbatini P, McCormick F.
Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis.
J Biol Chem.
1999;274:24263-24269
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. BALTAZIAK, M. KODA, A. WINCEWICZ, M. SULKOWSKA, L. KANCZUGA-KODA, and S. SULKOWSKI Relationships of P53 and Bak with EPO and EPOR in Human Colorectal Cancer Anticancer Res, October 1, 2009; 29(10): 4151 - 4156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Brown and S. Benchimol The Involvement of MAPK Signaling Pathways in Determining the Cellular Response to p53 Activation: CELL CYCLE ARREST OR APOPTOSIS J. Biol. Chem., February 17, 2006; 281(7): 3832 - 3840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Parsa, J. Kim, R. U. Riel, L. S. Pascal, R. B. Thompson, J. A. Petrofski, A. Matsumoto, J. S. Stamler, and W. J. Koch Cardioprotective Effects of Erythropoietin in the Reperfused Ischemic Heart: A POTENTIAL ROLE FOR CARDIAC FIBROBLASTS J. Biol. Chem., May 14, 2004; 279(20): 20655 - 20662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Barton, J. G. Karras, T. F. Murphy, A. Barton, and H. F-S. Huang Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines Mol. Cancer Ther., January 1, 2004; 3(1): 11 - 20. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
/
20°C as small
concentrated aliquots and added directly to the cell culture in
inhibition experiments. Recombinant human EPO was used at a
concentration of 1 U/mL.
m)
and free calcium content of DP16.1/p53ts cells cultured at 32°C in
the presence or absence of EPO were measured by flow cytometry. (C)
DP16.1/p53ts cells were cultured at 32°C in the presence or absence
of EPO for the times indicated. Protein extracts were prepared and
analyzed by SDS-PAGE and immunoblotting with anti-PARP antibodies. (D)
The generation of ROS and glutathione content of DP16.1/p53ts cells
cultured at 37°C or 32°C were measured by flow cytometry
(i-iii). ROS production in DP16.1/p53ts cells in response to
treatment with Tert-butyl-hydroperoxide is shown in panel iv (tBHP, 70 µM). Panel v represents an overlay of panels ii and iv.
-phosphatase indicating that that they could represent PKB-dependent
BAD phospho-forms (Figure 
irradiation was
similarly dependent on JAK2 and independent of STAT5 activation. Our
results provide a more direct assessment of JAK2 and STAT5 involvement
in EPO-mediated survival using an experimental model where apoptosis is
strictly dependent on p53.